A drug development company has raised $76 million from investors in China, the United States, and Korea to move its headquarters to the Philadelphia area from Jinan, China, and bring treatments developed by China-based scientists through U.S. clinical testing to patients here.
{iframe}http://www.philly.com/philly/blogs/inq-phillydeals/kpb-biosciences-gsk-ceo-brian-p-mcveigh-72m-china-pharma-philly-20180105.html{/iframe}